You are here


Diagnostics and Therapeutics for Adrenocortical Carcinomas

methods of diagnosing and treating malignant adrenocortical tumors, including adrenocortical carcinoma, using miRNA
NIH Reference Number
Product Type
  • Therapeutic
  • Diagnostic
  • Cancer
  • Adrenocortical Carcinomas (ACC)
  • miRNA
Collaboration Opportunity
This invention is available for licensing.
Description of Technology

The National Cancer Institute's Endocrine Oncology Branch seeks parties to co-develop diagnostic that target altered human miRNA expression such as miRNA-483 and miRNA 100 to accurately predict if a patient's adrenal cortex tumor is benign or malignant.

Adrenocortical carcinomas (ACC) are rare but aggressive cancers and typically have a poor prognosis.  Currently, there are limited options for molecular diagnosis to distinguish malignant tumors from benign tumors of this type.  As a result there are few treatment strategies for ACC.

This technology describes that altered human miRNA expression such as miRNA-483 and miRNA 100 can accurately predict if a patient''''s adrenal cortex tumor is benign or malignant. Additionally, preliminary results suggest that altering the expression of this miRNA in ACC cells can effect cancer cell growth.  Therefore, inhibiting a miRNA may serve as a therapeutic option for ACC.

Potential Commercial Applications
  • Technology can be developed into a diagnostic and prognostic marker for ACC.
  • Inhibiting miRNA can serve as a potential therapeutics for ACC.
Competitive Advantages
  • Distinguishes malignant Adrenal cortex tumor from a benign tumor, options for such distinction are limited at this time.

Electron Kebebew MD

Development Stage

Patterson E, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. [PMID: 21472710]

Patterson E, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. [PMID: 22241719]

Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 12/961,298, Filed 06 Dec 2010
Therapeutic Area
Wednesday, May 30, 2018